Eli Lilly’s retatrutide EAP: access for patients with 2+ severe comorbidities

For health systems and clinicians, Eli Lilly’s expanded access program for retatrutide presents both a clinical opportunity and an ethical challenge. While it could offer life-changing therapy for a small cohort of patients with refractory obesity and multiple severe conditions, the stringent criteria underscore how far we are from equitable access to effective obesity treatments. Health providers must now navigate the application process while grappling with reimbursement questions and the lack of long-term safety data outside trials.

Eli Lilly’s decision to offer an expanded access program (EAP) for its next-generation obesity drug retatrutide marks a notable shift in the fiercely competitive metabolic disease market. The company announced that a limited number of US patients with refractory obesity and severe comorbidities can receive the triple-agonist before FDA approval, expected filing in Q1 2027. Retatrutide’s mechanism targets GLP-1, GIP, and glucagon, differentiating it from Lilly’s own blockbuster Zepbound (tirzepatide, dual GLP-1/GIP) and from Novo Nordisk’s semaglutide franchise. Clinical data from an 80-week trial in adults with severe obesity and cardiovascular disease showed an average 22.6% weight loss at the highest dose, underscoring its potential as a best-in-class therapy.

“

Retatrutide’s mechanism targets GLP-1, GIP, and glucagon, differentiating it from Lilly’s own blockbuster Zepbound (tirzepatide, dual GLP-1/GIP) and from Novo Nordisk’s semaglutide franchise.

This move signals Lilly’s confidence in retatrutide’s safety and efficacy profile, while addressing an unmet need in a patient population with few alternatives. The eligibility criteria are stringent: adults with refractory obesity (inadequate response to the highest approved dose of anti-obesity medication), at least two serious obesity-related complications (e.g., type 2 diabetes, cardiovascular disease, sleep apnea), and inability to enroll in ongoing trials. By offering early access, Lilly navigates the FDA’s compassionate use pathway while building real-world evidence that could support future label expansions.

For patients, the program offers hope but also highlights the stark access gap in obesity care, where many insurers still don’t cover anti-obesity medications. Lilly’s direct provision of the drug could create a precedent for patient-funded or manufacturer-subsidized access models. However, limited supply and strict criteria mean only a small fraction of eligible patients will benefit. The company must also manage the ethical optics of granting early access while it races to secure a broad FDA label.

From a regulatory perspective, the EAP may accelerate real-world data collection on long-term safety and effectiveness, which could complement the pivotal TRIUMPH-Outcomes trial. Yet it also raises questions about equity — STAT News previously reported a single 79-year-old patient received special access, underscoring potential disparities until a formal program was established.